newsletter-fda-accepts-apitegromab-bla-first-muscle-targeted-sma-therapy-under-review

News post newsletter-fda-accepts-apitegromab-bla-first-muscle-targeted-sma-therapy-under-review from the SMA Research Platform — cited research evidence, computational findings and platform updates, loaded live from the database. SMA here means 5q spinal muscular atrophy, the SMN1-linked motor neuron disease — not α-SMA (alpha smooth muscle actin, ACTA2).